Sanofi India, NIPER partner to promote academic research

Sanofi India collaborates with the National Institute of Pharmaceutical Education and Research (NIPER) Kolkata to promote academic excellence and research

0
706

New Delhi: Sanofi India has entered into an agreement with NIPER Kolkata to promote academic excellence and research in the areas of pharmaceuticals and consumer healthcare products, to cater to the current and future needs of the pharmaceutical industry. The memorandum of understanding in this regard was signed in the presence of President of India, Mr Pranab Mukherjee.

NIPER Kolkata, an autonomous body set up under the aegis of Department of Pharmaceuticals, Government of India. Through this initiative, Sanofi India will participate in revision or formulation of curriculum for a Post-Graduate (M.S.)/Ph.D programme. It will provide opportunities of internship or project work to NIPER Kolkata M.S./Ph.D students at manufacturing sites besides ensuring association of R&D heads with the dissertation work of NIPER students. The program will provide career growth opportunities and undertake collaborative research activities in identified areas.

“The era of Academia-Industry collaboration to address the mammoth task of capacity building to meet our healthcare challenges has well and truly begun. Only a well-equipped and trained workforce can face future challenges and cater to the vast healthcare needs of the nation. We are proud to associate with NIPER Kolkata in this collaborative exercise to hone the students’ skill-sets, and empower them for future, based on our practical knowledge and research experience.” said Dr. Shailesh Ayyangar, Managing Director, Sanofi India Limited.

As per the MoU, the key deliverables for Sanofi India will be to assist NIPER Kolkata foster students with updated knowledge, and who are ready for the pharmaceutical industry. The collaboration will focus in the areas of NIPER Kolkata’s expertise including repurposing of existing pharmaceuticals and novel small molecules for anti-diabetics and drug-resistant tuberculosis, API by Synthetic Biology / Cell Factory, phyto-pharmaceuticals and rare diseases of public health importance.